TLR4 and bacterial pneumonia: Collectively, the data presented herein greatly extend our earlier observations of the relevance of treating influenza-induced ALI with TLR4 antagonists (12, –, 15) by further providing a rational therapeutic approach to ameliorate the lethal effects of the 2° bacterial pneumonia that often follows influenza virus infection.